Pfizer wins Norvasc patent challenge by Synthon

By Lisa Kerner

Charlotte, N.C., Sept. 1 - A federal court in the Middle District of North Carolina has upheld Pfizer Inc.'s U.S. patent covering amlodipine besylate, the active ingredient in the Norvasc-branded medicine for hypertension.

Generic manufacturer Synthon Pharmaceuticals had challenged U.S. Patent No. 4,879,303 and is now prohibited from launching a generic version of amlodipine until September 2007. The company can appeal.

Pfizer, a New York-based pharmaceutical company, said it will continue to defend any patent challenges.

An Illinois court found the same Norvasc patent valid and infringed by Apotex in January 2006.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.